AAV-hSyn-ZipV-2A-IvfChr (citrine, KV2.1)
(Plasmid
#221618)
-
PurposeA recombinant AAV2 plasmid encoding the ZipACR I151V mutant with soma targeting with KV2.1 motif and membrane expression enhanced vfChrimson-Citrine with soma targeting KV2.1 motif.
-
Depositing Lab
-
Publication
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 221618 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backboneAAV
- Backbone size w/o insert (bp) 4183
-
Vector typeAAV
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)NEB Stable
-
Copy numberUnknown
Gene/Insert
-
Gene/Insert nameZipACR (I151V)KV2.1-2A-IvfChr-citrine-Kv2.1
-
SpeciesSynthetic
-
Insert Size (bp)3258
-
MutationZipACR (I151V) with soma targeting, vfChrimson with membrane trafficking enhancement and soma targeting
- Promoter Human Synapsin
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site BamHI (not destroyed)
- 3′ cloning site XbaI (not destroyed)
Resource Information
-
Supplemental Documents
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
soma targeted ZipACR (I151V) and 2A mediated expression of membrane optimized vfChrimson and soma targeting, citrine as vfChrimson expression marker.
Please visit https://doi.org/10.7554/eLife.90327.1 for preprint.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
AAV-hSyn-ZipV-2A-IvfChr (citrine, KV2.1) was a gift from John Lin (Addgene plasmid # 221618 ; http://n2t.net/addgene:221618 ; RRID:Addgene_221618) -
For your References section:
Dual-color optical activation and suppression of neurons with high temporal precision. Mermet-Joret N, Moreno A, Zbela A, Ellendersen BE, Krauth N, von Philipsborn A, Piriz J, Lin JY, Nabavi S. eLife 2023 12:RP90327 10.7554/eLife.90327.1